

PORTOFOLIUL LUCRĂRILOR ȘTIINȚIFICE REPREZENTATIVE

Lucrări științifice de specialitate publicate în extenso în reviste cotate ISI

1. **Bălașa R**, Maier S, Voidăzan S, Huțanu A, Bajkó Z, Moțățăianu A, Țilea B, Tiu C. *Assessment of interleukin-17A, interleukin-10 and transforming growth factor-beta 1 serum titers in relapsing remitting multiple sclerosis patients treated with Avonex, possible biomarkers for treatment response*. CNS Neurol Disord Drug Targets 2016; 15: 000-000. **IF: 2.628.**
2. Maier S, Bajkó Z, Moțățăianu A, Rusu S, **Bălașa R**. *Giant internal carotid artery aneurysm causing Collet-Sicard syndrome*. Acta Neurol Belgica 2016; DOI: 10.1007/s13760-016-0644-z. **IF: 0.894.**
3. Bălașa A **Bălașa R**, Egyed-Zsigmond I, Chinezu R. *Bilateral thalamic glioma: case report and review of the literature*. Turk Neurosurg 2016; 26: 321-324. **IF: 0.576.**
4. Mărginean A, Bănescu C, Moldovan V, Scridon A, Mărginean M, **Bălașa R**, Maier S, Țăruși M, Doboreanu M. *The impact of CY2C19 polymorphism, clinical and demographic variables on platelet response to clopidogrel evaluated using impedance aggregometry*. Clin Appl Thromb/Hemost 2016; 22: DOI: 10.1177/1076029616629211. **IF: 2.392.**
5. **Bălașa R**, Maier S, Voidăzan S, Huțanu A, Bajkó Z, Moțățăianu A. *An intricate mechanism of action of Avonex in relapsing remitting multiple sclerosis patients: variation of serum titre of interleukin-17A, interleukin-10 and transforming growth factor-β*. CNS Neurol Disord Drug Targets 2015; 14: 804-810. **IF: 2.702.**
6. **Bălașa R**, Maier S, Bajkó Z, Pașcanu I, Moțățăianu A. *Skeletal muscle Na⁺/K⁺-ATPase pump dysfunction in thyrotoxic periodic paralysis: case report*. Acta Endocrinol (Buc) 2015; 11: 240-245. **IF: 0.210.**
7. **Bălașa R**, Maier S, Bajkó Z, Moțățăianu A, Crișan A, Bălașa A. *Longitudinally extensive transverse myelitis in neuromyelitis optica: a prospective study of 13 Caucasian patients and literature review*. Acta Neurol Belgica 2015; 115: 635-642. **IF: 0.598.**
8. Maier S, Buruian M, Maier A, Moțățăianu A, Voidăzan S, Bajkó Z, **Bălașa R**. *The determinants of depression in a Romanian cohort of multiple sclerosis patients*. Acta Neurol Belgica 2015; DOI: 10.1007/s13760-015-0547-4. **IF: 0.598.**
9. Bajkó Z, **Bălașa R**, Szatmári S, Rusu S, Moțățăianu A, Maier S. *The role of ultrasound in the diagnosis of temporal arteritis*. Neurol Neurochir Polska 2015; 49: 139-143. **IF: 0.641.**
10. Stoian A, Bănescu C, **Bălașa R**, Moțățăianu A, Stoian M, Moldovan VG, Voidăzan S, Doboreanu M. *Influence of GSTM1, and GSTP1 polymorphisms on type 2*

diabetes mellitus and diabetic sensorimotor peripheral neuropathy risk. Dis Markers 2015; ID 638693. **IF: 1.562.**

- 11.** Jung I, Gurzu S, **Bălașa R**, Moțățăianu A, Contac AO, Halmaciu I, Popescu S, Simu I. *A coin-like peripheral small lung carcinoma associated with acute paraneoplastic axonal Guillain-Barré-like syndrome.* *Medicine (Baltimore)* 2015; 94: e910. **IF: 4.256.**
- 12.** **Bălașa R**, Maier S, Gliga Baubec E, Bajkó Z, Bălașa A. *Cerebellar and brainstem variant of posterior reversible encephalopathy syndrome.* *Acta Neurol Belg* 2015; 115: 401-403. **IF: 0.598.**
- 13.** **Bălașa R**, Bajkó Z, Moțățăianu A, Maier A, Maier S. *Neuromyelitis optica associated with painful dystonia: case report and literature review.* *Acta Neurol Belg* 2015; 115: 169-171. **IF: 0.598.**
- 14.** **Bălașa R**, Maier S, Moțățăianu A, Bajkó Z, Moldovan O, Benedek E. *A case of fatal acute intermittent porphyria: laboratory diagnosis and pathogenesis considerations.* *Rev Rom Med Lab* 2014; 22: 325-333. **IF: 0.171.**
- 15.** Treabă AC, **Bălașa R**, Podoleanu DM, Simu IP, Buruian MM. *Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity?* *Diagn Interv Radiol* 2014; 20: 178-184. **IF: 1.427.**
- 16.** Moțățăianu A, **Bălașa R**, Voidăzan S, Bajkó Z. *Cardiovascular autonomic neuropathy in context of other complications of type 2 diabetes mellitus.* *BioMed Res Internat* 2013, Article ID 507216. **IF: 2.706.**
- 17.** **Bălașa R**, Bajkó Z, Huțanu A. *Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon- β .* *Mult Scler J* 2013; 19: 885-890. **IF: 4.863.**
- 18.** **Bălașa R**, Huțanu A, Bajkó Z, Feier C, Pascu I. *Does the serum IL-17 titer influence the efficacy of interferon- β treatment in multiple sclerosis?* *Rev Rom Med Lab* 2011; 19: 381-389, ISSN 1841-6624, **IF: 0.091.**
- 19.** **Bălașa R**, Huțanu A, Feier C, Bajkó Z, Pascu I. *Incidence and clinical significance of binding antibodies and their relationships with neutralizing antibodies, both induced by interferon- β treatment in multiple sclerosis patients.* *Rev Rom Med Lab* 2010; 18: 39-50. **IF: 0.113.**